Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
financial results for the first>quarter ended March 31, 2017.
The full text of the press release is attached as exhibit 99.1 to
this Current Report on Form 8-K.
information contained or incorporated herein, including the press
release filed as Exhibit 99.1, shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed to be
incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, whether made before
or after the date hereof, except as expressly set forth by
specific reference in such filing to this Current Report on Form
8-K.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release issued May 10, 2017, reporting financial
results for the first quarter ended March 31, 2017. |
About Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics, Inc. (NASDAQ:CDTX) Recent Trading Information
Cidara Therapeutics, Inc. (NASDAQ:CDTX) closed its last trading session up +0.10 at 6.85 with 102,578 shares trading hands.
